Evidence map›Paper›PMID 37053171›Full record

ArticlePloS one2023

Near point-of-care HIV viral load testing: Cascade after high viral load in suburban Yangon, Myanmar.

Ni Ni Tun, Frank Smithuis, Nyan Lynn Tun, Myo Min, Myo Ma Ma Hlaing, Josefien van Olmen, Lutgarde Lynen, Tinne Gils

Erratum issuedAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Ni Ni TunHIV/TB, Medical Action Myanmar, Yangon, Myanmar.ORCID 0000-0003-1496-7813
Frank SmithuisHIV/TB, Medical Action Myanmar, Yangon, Myanmar.
Nyan Lynn TunHIV/TB, Myanmar Oxford Clinical Research Unit, Yangon, Myanmar.ORCID 0000-0001-8789-1202
Myo MinHIV/TB, Myanmar Oxford Clinical Research Unit, Yangon, Myanmar.
Myo Ma Ma HlaingHIV/TB, Medical Action Myanmar, Yangon, Myanmar.
Josefien van OlmenSpearhead Research Public Health & Primary Care, University of Antwerp, Antwerp, Belgium.
Lutgarde LynenClinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Tinne GilsClinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-5518-9600

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHIV viral load (VL) testing in resource-limited settings is often centralised, limiting access. In Myanmar, we assessed outcomes according to VL access and the VL cascade (case management after a first high VL result) before and after near point-of-care (POC) VL was introduced.

methodsRoutine programme data from people living with HIV (PLHIV) on antiretroviral therapy (ART) were used. We assessed the odds of getting a VL test done by year. Attrition and mortality two years after ART initiation were compared between three groups of PLHIV with different access to VL testing using Kaplan-Meier analysis. We compared VL cascades in those with a first VL result before and after near POC VL testing became available. With logistic regression, predictors of confirmed virological failure after a first high VL in the POC era were explored.

resultsAmong 4291 PLHIV who started ART between July 2009 and June 2018, 794 (18.5%) became eligible for VL testing when it was not available, 2388 (55.7%) when centralised laboratory-based VL testing was available, and 1109 (25.8%) when near POC VL testing was available. Between 2010 and 2019, the odds of getting a VL test among those eligible increased with each year (OR: 5.21 [95% CI: 4.95-5.48]). Attrition and mortality were not different in the three groups. When comparing PLHIV with a first VL result before and after implementation of the near POC VL testing, in the latter, more had a first VL test (92% versus 15%, p<0.001), less had a first high VL result (5% versus 14%, p<0.001), and more had confirmed virological failure (67% versus 47%, p = 0.013). Having a first VL ≥5000 copies/mL after near POC implementation was associated with confirmed virological failure (adjusted OR: 2.61 [95% CI: 1.02-6.65]).

conclusionNear POC VL testing enabled rapid increase of VL coverage and a well-managed VL cascade in Myanmar.

Indexed as

Anti-HIV AgentsHIV InfectionsHumansMyanmarPoint-of-Care SystemsPoint-of-Care TestingSerologic TestsViral LoadAnti-HIV Agents

Identifiers

PMID37053171
PMCPMC10101411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.